These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 1568223)

  • 21. Effect of combination treatment with analogs of luteinizing hormone-releasing hormone (LH-RH) or somatostatin and 5-fluorouracil on pancreatic cancer in hamsters.
    Szepeshazi K; Lapis K; Schally AV
    Int J Cancer; 1991 Sep; 49(2):260-6. PubMed ID: 1679045
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of growth of HT-29 human colon cancer xenografts in nude mice by treatment with bombesin/gastrin releasing peptide antagonist (RC-3095).
    Radulovic S; Miller G; Schally AV
    Cancer Res; 1991 Nov; 51(21):6006-9. PubMed ID: 1682040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice.
    Jungwirth A; Galvan G; Pinski J; Halmos G; Szepeshazi K; Cai RZ; Groot K; Schally AV
    Prostate; 1997 Aug; 32(3):164-72. PubMed ID: 9254895
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Histological changes in Dunning prostate tumors and testes of rats treated with LH-RH antagonist SB-75.
    Szepeshazi K; Korkut E; Szende B; Lapis K; Schally AV
    Prostate; 1991; 18(3):255-70. PubMed ID: 2020621
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination of long-acting microcapsules of the D-tryptophan-6 analog of luteinizing hormone-releasing hormone with chemotherapy: investigation in the rat prostate cancer model.
    Schally AV; Redding TW
    Proc Natl Acad Sci U S A; 1985 Apr; 82(8):2498-502. PubMed ID: 3157990
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.
    Pinski J; Reile H; Halmos G; Groot K; Schally AV
    Cancer Res; 1994 Jan; 54(1):169-74. PubMed ID: 7903203
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II.
    Jungwirth A; Pinski J; Galvan G; Halmos G; Szepeshazi K; Cai RZ; Groot K; Vadillo-Buenfil M; Schally AV
    Eur J Cancer; 1997 Jun; 33(7):1141-8. PubMed ID: 9376196
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Suppression of meiosis of male germ cells by an antagonist of luteinizing hormone-releasing hormone.
    Szende B; Redding TW; Schally AV
    Proc Natl Acad Sci U S A; 1990 Feb; 87(3):901-3. PubMed ID: 2405399
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Decrease in the level and mRNA expression of LH-RH and EGF receptors after treatment with LH-RH antagonist cetrorelix in DU-145 prostate tumor xenografts in nude mice.
    Lamharzi N; Halmos G; Jungwirth A; Schally AV
    Int J Oncol; 1998 Sep; 13(3):429-35. PubMed ID: 9683774
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and luteinizing hormone-releasing hormone antagonist SB-75 on the growth of MCF-7 MIII human breast cancer xenografts in athymic nude mice.
    Yano T; Pinski J; Szepeshazi K; Halmos G; Radulovic S; Groot K; Schally AV
    Cancer; 1994 Feb; 73(4):1229-38. PubMed ID: 8313327
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibitory effects of analogs of luteinizing hormone-releasing hormone on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.
    Pinski J; Reile H; Halmos G; Groot K; Schally AV
    Int J Cancer; 1994 Oct; 59(1):51-5. PubMed ID: 7927904
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Direct effects of luteinizing hormone-releasing hormone agonists and antagonists on MCF-7 mammary cancer cells.
    Segal-Abramson T; Kitroser H; Levy J; Schally AV; Sharoni Y
    Proc Natl Acad Sci U S A; 1992 Mar; 89(6):2336-9. PubMed ID: 1312718
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factor.
    Plonowski A; Schally AV; Letsch M; Krupa M; Hebert F; Busto R; Groot K; Varga JL
    Prostate; 2002 Aug; 52(3):173-82. PubMed ID: 12111694
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of mammary tumor growth in rats and mice by administration of agonistic and antagonistic analogs of luteinizing hormone-releasing hormone.
    Redding TW; Schally AV
    Proc Natl Acad Sci U S A; 1983 Mar; 80(5):1459-62. PubMed ID: 6219395
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effective treatment of metastatic MDA-MB-435 human estrogen-independent breast carcinomas with a targeted cytotoxic analogue of luteinizing hormone-releasing hormone AN-207.
    Chatzistamou L; Schally AV; Nagy A; Armatis P; Szepeshazi K; Halmos G
    Clin Cancer Res; 2000 Oct; 6(10):4158-65. PubMed ID: 11051271
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238.
    Plonowski A; Schally AV; Nagy A; Sun B; Szepeshazi K
    Cancer Res; 1999 Apr; 59(8):1947-53. PubMed ID: 10213505
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of prostate tumor growth in two rat models by chronic administration of D-Trp6 analogue of luteinizing hormone-releasing hormone.
    Redding TW; Schally AV
    Proc Natl Acad Sci U S A; 1981 Oct; 78(10):6509-12. PubMed ID: 6458815
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of radioimmunoassay for a potent luteinizing hormone-releasing hormone antagonist. Evaluation of serum levels after injection of [Ac-3-(2-naphthyl)-D-Ala1, D-Phe(pCl)2, 3-(3-pyridyl)-D-Ala3, D-Cit6, D-Ala10] LHRH.
    Csernus VJ; Szende B; Groot K; Redding TW; Schally AV
    Arzneimittelforschung; 1990 Feb; 40(2 Pt 1):111-8. PubMed ID: 2110458
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of the growth of some hormone dependent tumors by D-Trp6-LH-RH.
    Schally AV; Redding TW; Comaru-Schally AM
    Med Oncol Tumor Pharmacother; 1984; 1(2):109-18. PubMed ID: 6242477
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Growth inhibition of estrogen independent MXT mouse mammary carcinomas in mice treated with an agonist or antagonist of LH-RH, an analog of somatostatin, or a combination.
    Szepeshazi K; Milovanovic S; Lapis K; Groot K; Schally AV
    Breast Cancer Res Treat; 1992; 21(3):181-92. PubMed ID: 1355375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.